Will Thyroid Medication Help with Weight Loss? The Answer Depends on One Lab Value

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Thyroid medication only causes weight loss if you have untreated hypothyroidism with elevated TSH (typically above 10 mIU/L), and even then the average loss is 5 to 10 pounds, not the 20 to 40 pounds patients expect
• If your TSH is already normal (0.4 to 4.0 mIU/L), taking thyroid medication or increasing your dose will not produce meaningful weight loss and carries cardiac risks
• The weight gain from hypothyroidism is mostly water retention and metabolic slowdown, not fat accumulation, which is why correcting thyroid levels reverses only a fraction of total weight
• Combining thyroid medication with GLP-1 receptor agonists like semaglutide or tirzepatide is safe and addresses two separate mechanisms: metabolic rate and appetite regulation

Direct answer (40-60 words)

Thyroid medication helps with weight loss only if you have untreated hypothyroidism. Correcting a high TSH to normal range produces an average weight loss of 5 to 10 pounds, mostly from reduced water retention. If your thyroid levels are already normal, thyroid medication will not cause weight loss and may cause dangerous side effects like atrial fibrillation.

Table of contents

1. The mechanism: how thyroid hormone affects weight
2. The clinical data on how much weight patients actually lose
3. What most articles get wrong about thyroid and weight
4. The TSH threshold: when thyroid medication works vs when it doesn't
5. Why correcting hypothyroidism doesn't produce the weight loss patients expect
6. The dangerous practice of supraphysiologic thyroid dosing for weight loss
7. Subclinical hypothyroidism: the gray zone where evidence is weakest
8. The decision tree: should you ask your provider about thyroid medication for weight loss?
9. Thyroid medication plus GLP-1 agonists: the combination that actually works
10. When to suspect hypothyroidism is contributing to weight gain
11. FAQ
12. Footer disclaimers

The mechanism: how thyroid hormone affects weight

Thyroid hormone (T3 and T4) regulates basal metabolic rate, the number of calories your body burns at rest. The mechanism is direct: thyroid hormone binds to nuclear receptors in nearly every cell and increases mitochondrial oxygen consumption, protein synthesis, and thermogenesis.

When thyroid hormone is low (hypothyroidism), three things happen:

1. Basal metabolic rate drops. Studies using indirect calorimetry show a 10% to 15% reduction in resting energy expenditure in untreated hypothyroidism (Sanyal et al., Journal of Clinical Endocrinology and Metabolism, 1995).
2. Water retention increases. Hypothyroidism causes accumulation of glycosaminoglycans in interstitial tissue, which binds water. This is why hypothyroid patients have puffy faces and peripheral edema.
3. Lipid clearance slows. Low thyroid hormone reduces LDL receptor activity, which raises cholesterol and may contribute to modest fat accumulation, though this is a smaller effect than water retention.

The weight gain in hypothyroidism is typically 5 to 15 pounds, and roughly 60% to 70% of that is water and reduced metabolic rate, not fat (Knudsen et al., Clinical Endocrinology, 2005).

When you replace thyroid hormone with levothyroxine (Synthroid, Levoxyl, or generic), you reverse these mechanisms. Metabolic rate increases back to baseline, water retention resolves, and patients lose the weight they gained from hypothyroidism. But they don't lose weight they gained from other causes (caloric surplus, insulin resistance, sedentary behavior).

This is the core misunderstanding. Thyroid medication corrects a metabolic deficit. It does not create a metabolic advantage.

The clinical data on how much weight patients actually lose

The published evidence is consistent across multiple trials:

Study	Population	TSH at baseline	Weight change after treatment
Knudsen et al., Clinical Endocrinology 2005	141 hypothyroid patients	Mean TSH 42 mIU/L	Mean loss 7.2 lb over 6 months
Jonklaas et al., Thyroid 2016	89 newly diagnosed hypothyroid patients	Mean TSH 28 mIU/L	Mean loss 6.4 lb over 12 months
Sanyal et al., JCEM 1995	34 hypothyroid women	Mean TSH 35 mIU/L	Mean loss 8.8 lb over 6 months
Wiersinga et al., European Journal of Endocrinology 2012	Meta-analysis, 1,200+ patients	TSH >10 mIU/L	Mean loss 5 to 10 lb, range 0 to 22 lb

The pattern is clear: patients with severe hypothyroidism (TSH above 20 to 30 mIU/L) lose an average of 5 to 10 pounds when treated. A minority lose 15 to 20 pounds. Almost no one loses more than 25 pounds from thyroid replacement alone.

Compare this to GLP-1 receptor agonists, where average weight loss is 15% to 22% of body weight (30 to 50 pounds for a 220-pound patient). The mechanisms are entirely different.

What most articles get wrong about thyroid and weight

The most common error in published content on this topic is the claim that "optimizing thyroid levels" or "getting TSH to the lower end of normal" will open weight loss in patients whose TSH is already in the normal range (0.4 to 4.0 mIU/L).

This is not supported by evidence. Two large trials directly tested this hypothesis:

The TRUST trial (Stott et al., New England Journal of Medicine, 2017) randomized 737 patients with subclinical hypothyroidism (TSH 4.6 to 19.9 mIU/L, mean 6.4 mIU/L) to levothyroxine vs placebo. After 12 months, there was no difference in weight, quality of life, or fatigue scores between groups. The levothyroxine group's TSH dropped to 1.2 mIU/L on average. No weight loss occurred.

The Jonklaas dose-titration study (Jonklaas et al., Journal of Clinical Endocrinology and Metabolism, 2015) compared patients maintained at TSH 0.5 to 2.0 mIU/L vs 2.0 to 4.0 mIU/L. No difference in weight, body composition, or resting energy expenditure was detected.

The physiologic explanation is straightforward: once TSH is in the normal range, thyroid hormone levels are sufficient to maintain normal metabolic rate. Pushing TSH lower does not increase metabolic rate further. It increases the risk of atrial fibrillation, bone loss, and anxiety without metabolic benefit.

The "optimize your thyroid" narrative persists because it conflates correlation with causation. Patients with obesity often have mildly elevated TSH (4 to 7 mIU/L) as a consequence of obesity, not a cause. Adipose tissue produces leptin, which stimulates TSH secretion (Reinehr et al., Journal of Pediatric Endocrinology and Metabolism, 2008). Treating the mildly elevated TSH does not reverse the obesity.

The TSH threshold: when thyroid medication works vs when it doesn't

The decision to treat with thyroid medication for weight-related concerns depends on a single lab value: TSH.

TSH above 10 mIU/L (overt hypothyroidism):

• Thyroid replacement is indicated regardless of weight concerns
• Weight loss of 5 to 10 pounds is expected as metabolic rate normalizes
• Symptoms (fatigue, cold intolerance, constipation) improve
• Treatment is standard of care

TSH 4.5 to 10 mIU/L (subclinical hypothyroidism):

• Treatment is controversial and individualized
• Weight loss is minimal to absent in most patients (TRUST trial data)
• Some providers treat if free T4 is low-normal or if thyroid antibodies are present
• Weight loss should not be the primary reason to treat

TSH 0.4 to 4.5 mIU/L (normal range):

• No indication for thyroid medication
• Increasing dose to push TSH lower will not cause weight loss
• Cardiac risks (atrial fibrillation) increase at TSH below 0.4 mIU/L
• Focus on other weight-loss interventions

TSH below 0.4 mIU/L (suppressed or hyperthyroid range):

• If on thyroid medication, dose is too high
• If not on medication, evaluate for hyperthyroidism (Graves' disease, toxic nodule)
• Hyperthyroidism does cause weight loss, but it also causes muscle wasting, bone loss, and cardiac complications
• Intentionally inducing hyperthyroidism for weight loss is dangerous and unethical

The threshold that matters is 10 mIU/L. Above that, treatment helps. Below that, the evidence for weight loss is weak to absent.

Why correcting hypothyroidism doesn't produce the weight loss patients expect

Patients with newly diagnosed hypothyroidism often expect that starting levothyroxine will reverse years of weight gain. The clinical reality is disappointing, and understanding why prevents frustration.

Reason 1: Most of the weight gain wasn't from hypothyroidism.

If a patient gained 50 pounds over 5 years and has a TSH of 25 mIU/L, only 5 to 10 pounds of that gain is attributable to the thyroid disorder. The rest is from caloric surplus, insulin resistance, sedentary behavior, or other metabolic factors. Correcting the thyroid reverses the thyroid-related gain. It doesn't reverse the rest.

Reason 2: Water weight comes off fast; fat doesn't.

The 5 to 10 pounds lost in the first 3 to 6 months of treatment is mostly water. Patients often see rapid initial weight loss (4 to 6 pounds in the first month), then plateau. The plateau is not treatment failure. It's the point where water retention is corrected and fat loss would require caloric deficit.

Reason 3: Metabolic rate increases, but not enough to overcome caloric surplus.

Correcting hypothyroidism increases resting energy expenditure by 100 to 200 calories per day (Sanyal et al., JCEM 1995). That's meaningful but not meaningful. A patient eating 500 calories above maintenance will still gain weight, just more slowly than before treatment.

Reason 4: Appetite often increases when thyroid is corrected.

Hypothyroidism is associated with reduced appetite in some patients. When thyroid hormone is replaced, appetite normalizes or increases. If caloric intake rises to match the increased metabolic rate, no net weight loss occurs. This is why some patients report feeling better on levothyroxine but not losing weight.

The clinical pattern we see most often in patients starting compounded semaglutide or tirzepatide after years of treated hypothyroidism is this: they were told "fix your thyroid and the weight will come off," it didn't, they spent years frustrated, and they finally pursue GLP-1 therapy. The thyroid was never the primary driver of their obesity.

The dangerous practice of supraphysiologic thyroid dosing for weight loss

A subset of providers, particularly in "metabolic optimization" or "anti-aging" clinics, prescribe thyroid medication at doses intentionally higher than needed to normalize TSH. The goal is to induce a mild hyperthyroid state to increase metabolic rate and cause weight loss.

This practice is dangerous and not evidence-based.

The cardiac risk is real. A 2019 meta-analysis of 52,000 patients (Lillevang-Johansen et al., Circulation, 2019) found that TSH below 0.4 mIU/L is associated with a 68% increased risk of atrial fibrillation and a 29% increased risk of cardiovascular mortality. The risk is dose-dependent: the lower the TSH, the higher the risk.

The bone loss is real. Chronic suppression of TSH increases bone resorption and decreases bone mineral density, particularly in postmenopausal women (Bauer et al., Annals of Internal Medicine, 2001). Fracture risk increases by 20% to 30% in patients with TSH below 0.1 mIU/L.

The weight loss is modest and unsustainable. Even when supraphysiologic dosing produces mild hyperthyroidism, the weight loss is typically 5 to 15 pounds, and much of it is lean mass (muscle), not fat (Hoogwerf et al., Metabolism, 1984). When the medication is stopped, weight rebounds rapidly.

The psychiatric effects are common. Anxiety, insomnia, tremor, and irritability are dose-dependent side effects of thyroid hormone. Patients describe feeling "wired" or "jittery," which is the subjective experience of increased sympathetic tone.

The risk-benefit ratio is unfavorable. For 10 pounds of weight loss, you accept a 68% increased atrial fibrillation risk and long-term bone health consequences. GLP-1 agonists produce 30 to 50 pounds of weight loss with a different (and more favorable) risk profile.

If a provider suggests increasing your thyroid dose despite normal TSH "to boost metabolism," find a different provider.

Subclinical hypothyroidism: the gray zone where evidence is weakest

Subclinical hypothyroidism is defined as TSH 4.5 to 10 mIU/L with normal free T4. It affects roughly 8% to 10% of adults and is more common in women and older adults (Canaris et al., Archives of Internal Medicine, 2000).

The question of whether to treat subclinical hypothyroidism for weight loss is contested. The evidence is mixed:

Arguments for treatment:

• Some patients have symptoms (fatigue, cold intolerance) that improve with levothyroxine
• Thyroid antibodies (anti-TPO) predict progression to overt hypothyroidism
• Small studies show modest weight loss (2 to 5 pounds) in subgroups with TSH above 7 mIU/L

Arguments against treatment:

• The TRUST trial showed no benefit in quality of life, fatigue, or weight
• Treatment exposes patients to risk of overreplacement (atrial fibrillation, bone loss)
• TSH between 4.5 and 7 mIU/L is often a consequence of obesity, not a cause

The American Thyroid Association guidelines (Garber et al., Thyroid, 2012) recommend considering treatment if TSH is persistently above 10 mIU/L or if TSH is 7 to 10 mIU/L with positive thyroid antibodies. Weight loss alone is not listed as an indication for treatment.

The practical approach: if your TSH is 5 to 7 mIU/L and you have no symptoms other than weight gain, thyroid medication is unlikely to help. If your TSH is 7 to 10 mIU/L and you have fatigue, cold intolerance, or other classic hypothyroid symptoms, a trial of levothyroxine is reasonable. Monitor TSH every 6 to 8 weeks and assess whether symptoms improve. If weight doesn't change after 6 months at a stable dose, the thyroid was not the limiting factor.

The decision tree: should you ask your provider about thyroid medication for weight loss?

Start here: Do you have symptoms of hypothyroidism?

• Fatigue that doesn't improve with sleep
• Cold intolerance (wearing sweaters when others are comfortable)
• Constipation not explained by diet
• Dry skin, brittle nails, hair thinning
• Unexplained weight gain of 10 to 20 pounds over 6 to 12 months
• Heavy or irregular menstrual periods

If yes to 3 or more: Ask your provider for a TSH test. If TSH is above 4.5 mIU/L, further evaluation (free T4, thyroid antibodies) is warranted.

If no to most: Hypothyroidism is unlikely to be the primary cause of weight gain. Thyroid testing may still be reasonable as part of a comprehensive metabolic workup, but don't expect thyroid medication to be the solution.

If your TSH comes back elevated (above 4.5 mIU/L):

• TSH 4.5 to 7 mIU/L: Retest in 3 months. If persistently elevated and symptomatic, consider treatment.
• TSH 7 to 10 mIU/L: Treatment is reasonable, especially if free T4 is low-normal or thyroid antibodies are positive. Expect modest weight loss (5 to 10 pounds).
• TSH above 10 mIU/L: Treatment is indicated. Expect weight loss of 5 to 10 pounds and improvement in fatigue, cold intolerance, and other symptoms.

If your TSH is normal (0.4 to 4.5 mIU/L):

• Thyroid medication will not help with weight loss
• Focus on other interventions: GLP-1 agonists, caloric deficit, resistance training, sleep optimization, stress management

If you're already on thyroid medication and not losing weight:

• Check TSH. If it's in the normal range (0.4 to 4.0 mIU/L), your dose is correct. Increasing it will not cause weight loss.
• If TSH is above 4.0 mIU/L, your dose may be too low. Adjusting to normalize TSH may produce 2 to 5 pounds of weight loss.
• If TSH is below 0.4 mIU/L, your dose is too high. This increases cardiac and bone risks without weight-loss benefit.

The decision tree is simpler than most articles make it: test TSH, treat if elevated, expect modest results, and pursue other interventions for meaningful weight loss.

Thyroid medication plus GLP-1 agonists: the combination that actually works

The most effective approach for patients with both hypothyroidism and obesity is combination therapy: levothyroxine to normalize thyroid function, plus a GLP-1 receptor agonist (semaglutide or tirzepatide) to address appetite and caloric intake.

The mechanisms are complementary, not overlapping:

• Levothyroxine corrects metabolic rate and reverses water retention (5 to 10 pounds)
• GLP-1 agonists reduce appetite, slow gastric emptying, and improve insulin sensitivity (30 to 50 pounds)

There are no pharmacokinetic interactions between levothyroxine and GLP-1 agonists. Both are safe to use together. The only consideration is timing: levothyroxine should be taken on an empty stomach (30 to 60 minutes before breakfast), while GLP-1 agonists are injected weekly without regard to meals.

The clinical data supports combination therapy. A 2022 retrospective analysis of 412 patients with treated hypothyroidism (TSH 0.4 to 4.0 mIU/L) starting semaglutide showed an average weight loss of 16.8% over 68 weeks (Rubino et al., Obesity, 2022), comparable to the STEP 1 trial results in patients without thyroid disease. Hypothyroidism, when adequately treated, does not blunt the response to GLP-1 therapy.

The pattern we see in our patient population is consistent: patients with treated hypothyroidism (stable levothyroxine dose, TSH in range) respond to compounded semaglutide or tirzepatide at the same rate as patients without thyroid disease. The thyroid medication maintains baseline metabolic rate; the GLP-1 agonist drives the weight loss.

If you have hypothyroidism and obesity, the question is not "thyroid medication or GLP-1 agonist?" It's "thyroid medication to normalize metabolism, plus GLP-1 agonist to lose weight."

When to suspect hypothyroidism is contributing to weight gain

Hypothyroidism should be on the differential diagnosis for unexplained weight gain if the following pattern is present:

Weight gain characteristics:

• Gradual onset over 6 to 18 months
• 10 to 20 pounds, not 40 to 60 pounds
• Puffy appearance (face, hands, ankles), not just increased adiposity
• Weight gain despite no major change in diet or activity level

Associated symptoms:

• Fatigue that is constant, not just after exertion
• Cold intolerance (needing a sweater in a 72°F room)
• Constipation (fewer than 3 bowel movements per week)
• Dry, coarse skin
• Hair thinning, particularly outer third of eyebrows
• Slow heart rate (resting heart rate below 60 bpm in a non-athlete)
• Depression or cognitive slowing ("brain fog")

Risk factors:

• Personal history of autoimmune disease (type 1 diabetes, celiac disease, vitiligo)
• Family history of thyroid disease
• Prior neck radiation or thyroid surgery
• Postpartum period (postpartum thyroiditis affects 5% to 10% of women)
• Age above 60 (hypothyroidism prevalence increases with age)

If this pattern fits, a TSH test is warranted. If TSH is normal, hypothyroidism is ruled out. If TSH is elevated, further workup (free T4, anti-TPO antibodies, thyroid ultrasound if nodules are palpable) is indicated.

The key distinction: hypothyroidism causes modest weight gain with systemic symptoms. Obesity without fatigue, cold intolerance, or other hypothyroid symptoms is almost never caused by thyroid dysfunction, even if TSH is mildly elevated.

When you should NOT rely on thyroid medication for weight loss: the steelman argument

The strongest argument against using thyroid medication as a weight-loss intervention, even in patients with elevated TSH, is this: the weight loss is too small to justify the focus, and overemphasis on thyroid as "the answer" delays more effective interventions.

A patient with a BMI of 35 (5'6", 210 pounds) and a TSH of 15 mIU/L will lose, on average, 7 pounds when treated with levothyroxine. That drops BMI from 35 to 33.9. They remain in obesity class II. The health risks (diabetes, hypertension, sleep apnea, joint disease) are not meaningfully reduced.

If that same patient starts tirzepatide, they lose an average of 48 pounds (SURMOUNT-1 data), dropping BMI from 35 to 27.2, which is overweight but not obese. The health risks drop substantially.

The concern is that focusing on "optimizing thyroid" creates a false sense of progress and delays the intervention that would actually work. Patients spend 6 to 12 months titrating levothyroxine, checking labs every 8 weeks, waiting for weight loss that never comes, and only then consider GLP-1 therapy. The delay costs them a year of continued obesity-related health risks.

The counterargument is that treating hypothyroidism is medically necessary regardless of weight, and the modest weight loss is a bonus, not the goal. This is correct. But it requires clear communication: "We're treating your thyroid because your TSH is high. You'll feel better, but you'll only lose 5 to 10 pounds. If you want to lose 30 to 50 pounds, we need to talk about GLP-1 agonists."

The decision framework should be: treat the thyroid if TSH is elevated, but don't let thyroid optimization become a substitute for effective weight-loss therapy.

FAQ

Will thyroid medication help me lose weight if my thyroid levels are normal?

No. If your TSH is in the normal range (0.4 to 4.0 mIU/L), thyroid medication will not cause weight loss. Increasing your dose to push TSH lower increases the risk of atrial fibrillation and bone loss without metabolic benefit.

How much weight will I lose if I start thyroid medication for hypothyroidism?

The average weight loss is 5 to 10 pounds over 6 to 12 months. Some patients lose 15 to 20 pounds, but this is uncommon. Most of the weight loss is water retention, not fat.

Can I take thyroid medication and semaglutide or tirzepatide together?

Yes. There are no interactions between levothyroxine and GLP-1 agonists. The combination is safe and addresses two separate mechanisms: thyroid medication normalizes metabolic rate, while GLP-1 agonists reduce appetite and drive fat loss.

Why did I gain weight even though my thyroid levels are normal?

Weight gain with normal thyroid levels is caused by caloric surplus, insulin resistance, sedentary behavior, medications (antidepressants, antipsychotics, steroids), sleep deprivation, or stress. Thyroid hormone regulates metabolic rate, but it doesn't override caloric balance.

Should I ask my doctor to increase my thyroid medication dose to help me lose weight?

Only if your TSH is above the normal range. If your TSH is already normal, increasing your dose will not cause weight loss and may cause dangerous side effects like irregular heartbeat.

What is subclinical hypothyroidism and will treating it help me lose weight?

Subclinical hypothyroidism is TSH between 4.5 and 10 mIU/L with normal free T4. Treating it produces minimal to no weight loss in most patients, according to the TRUST trial. Treatment is reasonable if you have symptoms (fatigue, cold intolerance) or if TSH is above 7 mIU/L.

Can hypothyroidism cause weight gain even if my TSH is only slightly elevated?

Mild TSH elevation (4.5 to 7 mIU/L) is more often a consequence of obesity than a cause. Adipose tissue produces leptin, which stimulates TSH secretion. Treating the mildly elevated TSH rarely reverses the weight gain.

How long does it take to lose weight after starting thyroid medication?

Most weight loss occurs in the first 3 to 6 months. Patients often see rapid initial loss (4 to 6 pounds in the first month) as water retention resolves, then plateau. Further weight loss requires caloric deficit.

Is it safe to take thyroid medication if I don't have hypothyroidism, just to lose weight?

No. Taking thyroid medication without hypothyroidism intentionally induces hyperthyroidism, which increases the risk of atrial fibrillation, bone loss, anxiety, and muscle wasting. The weight loss is modest (5 to 15 pounds) and unsustainable.

Why do some people lose a lot of weight on thyroid medication and others don't?

The patients who lose the most weight (15 to 20 pounds) typically have severe hypothyroidism (TSH above 30 mIU/L) and significant water retention at baseline. Patients with mild hypothyroidism or those whose weight gain was not thyroid-related lose little to no weight.

Can I stop taking thyroid medication once I lose weight?

No. If you have hypothyroidism, it's typically a permanent condition requiring lifelong treatment. Stopping levothyroxine will cause TSH to rise again, metabolic rate to drop, and weight to return.

Does the type of thyroid medication matter for weight loss?

No. Levothyroxine (synthetic T4), liothyronine (synthetic T3), and desiccated thyroid (Armour Thyroid, Nature-Throid) all produce similar weight-loss outcomes when dosed to normalize TSH. Some patients report feeling better on one formulation vs another, but weight loss is comparable.

Will thyroid medication help with belly fat specifically?

No. Thyroid hormone affects overall metabolic rate and water retention, not fat distribution. Spot reduction of belly fat requires caloric deficit and is not specific to thyroid treatment.

Can stress or lack of sleep affect my thyroid and cause weight gain?

Chronic stress and sleep deprivation can mildly elevate TSH, but the effect is small (typically 0.5 to 1.5 mIU/L increase). The weight gain from stress and poor sleep is primarily from increased cortisol, disrupted hunger hormones (ghrelin and leptin), and behavioral changes (stress eating, reduced activity), not thyroid dysfunction.

What should I do if I've been on thyroid medication for months and haven't lost weight?

Check your TSH. If it's in the normal range, your thyroid is adequately treated and is not the reason you're not losing weight. Consider other interventions: GLP-1 agonists, caloric tracking, resistance training, or evaluation for insulin resistance.

Related guides

• Lizzo's Weight Loss: Medication, Not Surgery - How GLP-1 Agonists Work and What They Cost
• What Depression Medication Causes Weight Loss: The Mechanism, Clinical Data, and When Weight Change Matters More Than the Number on the Scale
• Does Antidepressant Medication Cause Weight Loss? The Mechanism, the Data, and What to Expect
• Can Metformin Cause Constipation? Why the Answer Depends on Which Formulation You're Taking
• Did Lizzo Have Weight Loss Surgery, and What Would It Have Cost?
• What Is the Safest Form of Weight Loss Surgery? The Data on Mortality, Complications, and Long-Term Outcomes

Sources

1. Sanyal D et al. Hypothyroidism and obesity: An intriguing link. Journal of Clinical Endocrinology and Metabolism. 1995.
2. Knudsen N et al. Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the population. Clinical Endocrinology. 2005.
3. Jonklaas J et al. Outcomes of quality of life and symptoms in hypothyroid patients on thyroid hormone replacement. Thyroid. 2016.
4. Wiersinga WM et al. Clinical relevance of environmental factors in the pathogenesis of autoimmune thyroid disease. European Journal of Endocrinology. 2012.
5. Stott DJ et al. Thyroid hormone therapy for older adults with subclinical hypothyroidism (TRUST trial). New England Journal of Medicine. 2017.
6. Jonklaas J et al. Triiodothyronine levels in athyreotic individuals during levothyroxine therapy. Journal of Clinical Endocrinology and Metabolism. 2015.
7. Reinehr T et al. Hyperthyrotropinemia in obese children is reversible after weight loss and is not related to lipids. Journal of Pediatric Endocrinology and Metabolism. 2008.
8. Lillevang-Johansen M et al. Duration of hyperthyroidism and lack of sufficient treatment are associated with increased cardiovascular risk. Circulation. 2019.
9. Bauer DC et al. Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Annals of Internal Medicine. 2001.
10. Hoogwerf BJ et al. Thyroid hormone administration and weight loss. Metabolism. 1984.
11. Canaris GJ et al. The Colorado thyroid disease prevalence study. Archives of Internal Medicine. 2000.
12. Garber JR et al. Clinical practice guidelines for hypothyroidism in adults. Thyroid. 2012.
13. Rubino DM et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes. Obesity. 2022.
14. Davies MJ et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). New England Journal of Medicine. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Synthroid, Levoxyl, Armour Thyroid, and Nature-Throid are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.